

Richard D Carvajal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4213408/publications.pdf>

Version: 2024-02-01

159
papers

10,116
citations

76196

40
h-index

39575

94
g-index

163
all docs

163
docs citations

163
times ranked

13242
citing authors

#	ARTICLE	IF	CITATIONS
1	Uveal Melanoma Exosomes Induce a Prometastatic Microenvironment through Macrophage Migration Inhibitory Factor. <i>Molecular Cancer Research</i> , 2022, 20, 661-669.	1.5	21
2	Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 997-1004.	1.4	7
3	Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. , 2022, 10, e003776.		79
4	Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1939-1948.	0.8	29
5	New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma. <i>Cancer Gene Therapy</i> , 2022, 29, 1819-1826.	2.2	10
6	Capturing uveal melanoma (UM) global practice patterns and clinical outcomes in the collaborative ocular melanoma natural history (OMNi) study (NCT04588662).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9610-TPS9610.	0.8	0
7	A phase II study of biomarker-driven early discontinuation of anti-PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9591-TPS9591.	0.8	1
8	ARTISTRY-6: Nemvaleukin alfa monotherapy in patients with advanced mucosal and cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9609-TPS9609.	0.8	0
9	A phase I trial of the bifunctional EGFR/TGF β 2 fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2513-2513.	0.8	5
10	OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 460-472.	3.2	48
11	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. <i>European Radiology</i> , 2021, 31, 1853-1862.	2.3	10
12	Extracutaneous Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 85-98.	0.9	3
13	Arginine depletion as a therapeutic approach for patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 102, 566-570.	1.5	45
14	MicroRNA-Based Cancer Mortality Risk Scoring System and hTERT Expression in Early-Stage Oral Squamous Cell Carcinoma. <i>Journal of Oncology</i> , 2021, 2021, 1-11.	0.6	1
15	Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. , 2021, 9, e001931.		46
16	Cellular therapy for the treatment of solid tumors. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103056.	0.5	10
17	Dual Immunological Checkpoint Blockade for Uveal Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 554-556.	0.8	9
18	Analysis of malignant melanoma risk and outcomes in solid organ transplant recipients: Assessment of transplant candidacy and the potential role of checkpoint inhibitors. <i>Clinical Transplantation</i> , 2021, 35, e14264.	0.8	3

#	ARTICLE	IF	CITATIONS
19	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	1.0	51
20	First-in-human phase I study of the bifunctional EGFR/TGF β 2 fusion protein BCA101 in patients with EGFR-driven advanced solid cancers.. Journal of Clinical Oncology, 2021, 39, 3074-3074.	0.8	4
21	Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts).. Journal of Clinical Oncology, 2021, 39, e21513-e21513.	0.8	1
22	Phase 1b/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma.. Journal of Clinical Oncology, 2021, 39, 3018-3018.	0.8	3
23	Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).. Journal of Clinical Oncology, 2021, 39, 9531-9531.	0.8	3
24	Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI).. Journal of Clinical Oncology, 2021, 39, 9535-9535.	0.8	9
25	Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma.. Journal of Clinical Oncology, 2021, 39, 9527-9527.	0.8	8
26	Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.. Journal of Clinical Oncology, 2021, 39, 2549-2549.	0.8	21
27	Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.. Journal of Clinical Oncology, 2021, 39, 9526-9526.	0.8	6
28	Initial findings of the first-in-human phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 2634-2634.	0.8	3
29	Abstract CT038: Kinetics of radiographic response for tebentafusp (tebe) in previously treated metastatic uveal melanoma (mUM) patients (pts) achieving prolonged survival. , 2021, , .		3
30	Abstract CT002: Phase 3 randomized trial comparing tebentafusp with investigator's choice in first line metastatic uveal melanoma. Cancer Research, 2021, 81, CT002-CT002.	0.4	10
31	Multiregional genetic evolution of metastatic uveal melanoma. Npj Genomic Medicine, 2021, 6, 70.	1.7	9
32	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. New England Journal of Medicine, 2021, 385, 1196-1206.	13.9	376
33	Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission. , 2021, 9, e001219.		4
34	A Phase 1b Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3K Inhibitor, in Patients with Metastatic Uveal Melanoma. Cancers, 2021, 13, 5504.	1.7	18
35	819...Radiomic markers associated with clinical benefit in advanced uveal melanoma patients with radiographic progression on tebentafusp. , 2021, 9, A857-A857.		1
36	538...Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp. , 2021, 9, A568-A568.		2

#	ARTICLE	IF	CITATIONS
37	Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence. <i>Frontiers in Oncology</i> , 2021, 11, 734354.	1.3	17
38	Advances in Prevention and Surveillance of Cutaneous Malignancies. <i>American Journal of Medicine</i> , 2020, 133, 417-423.	0.6	19
39	Case of Merkel cell carcinoma in a patient with pre-existing ILD. , 2020, 8, e001672.		1
40	Novel Approaches to the Systemic Management of Uveal Melanoma. <i>Current Oncology Reports</i> , 2020, 22, 104.	1.8	9
41	Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019,) Tj ETQq1.1 0.784314 rgBT /	1.8	5
42	Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology. <i>JCO Precision Oncology</i> , 2020, 4, 1038-1048.	1.5	16
43	Pembrolizumab and tavokinogene telseplasmid electroporation in metastatic melanoma. <i>International Journal of Surgery Case Reports</i> , 2020, 77, 591-594.	0.2	3
44	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). <i>Melanoma Management</i> , 2020, 7, MMT41.	0.1	3
45	Perspectives on the recommendations for skin cancer management during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 295-296.	0.6	20
46	Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients. , 2020, 8, e000908.		18
47	Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1031-1039.	1.9	41
48	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. , 2020, 8, e000331.		66
49	Conjunctival Melanoma: Current Treatments and Future Options. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 371-381.	3.3	33
50	MicroRNA-based risk scoring system to identify early-stage oral squamous cell carcinoma patients at high-risk for cancer-specific mortality. <i>Head and Neck</i> , 2020, 42, 1699-1712.	0.9	27
51	Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma. <i>Cancer Research</i> , 2020, 80, 1078-1087.	0.4	18
52	Uveal melanoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 24.	18.1	392
53	First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020, 26, 1025-1033.	3.2	45
54	377...AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects. , 2020, , .		4

#	ARTICLE	IF	CITATIONS
55	401â€¦Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. , 2020, , .		2
56	Use of antibody arrays to probe exosome and extracellular vesicle mediated functional changes in cells. <i>Methods in Enzymology</i> , 2020, 645, 43-53.	0.4	4
57	Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 971.	1.7	87
58	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Nonâ€“Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019, 5, 1411.	3.4	388
59	An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6709-6720.	3.2	32
60	Novel Targets for the Treatment of Melanoma. <i>Current Oncology Reports</i> , 2019, 21, 97.	1.8	15
61	Dual checkpoint inhibitor-associated eosinophilic enteritis. , 2019, 7, 310.		16
62	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. <i>Cancers</i> , 2019, 11, 1642.	1.7	47
63	Mucosal melanoma: current strategies and future directions. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 427-434.	0.5	2
64	Chemoreduction of Orbital Recurrence of Uveal Melanoma by Intra-Arterial Melphalan. <i>Ocular Oncology and Pathology</i> , 2019, 5, 186-189.	0.5	4
65	Inhibition of NF-Î²â€“Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma. <i>Cancer Research</i> , 2019, 79, 2415-2425.	0.4	31
66	Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	49
67	KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 315-323.	3.3	64
68	Abstract CT068: A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma. <i>Cancer Research</i> , 2019, 79, CT068-CT068.	0.4	21
69	Clinical utility and reimbursement for expanded genomic panel testing in adult oncology.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6593-6593.	0.8	4
70	Phase II single-arm multicenter study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9604-TPS9604.	0.8	3
71	CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 549-549.	0.8	44
72	Resensitization of uveal melanoma (UM) to immune checkpoint inhibition (ICI) by IMCgp100 (IMC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9592-9592.	0.8	4

#	ARTICLE	IF	CITATIONS
73	Treatment of uveal melanoma: where are we now?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883401875717.	1.4	224
74	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research, 2018, 24, 1881-1890.	3.2	59
75	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discovery, 2018, 8, 184-195.	7.7	283
76	JAK-ing up the Response to KIT Inhibition. Journal of Investigative Dermatology, 2018, 138, 6-8.	0.3	2
77	The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma. Clinical Cancer Research, 2018, 24, 3477-3479.	3.2	5
78	A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. Investigational New Drugs, 2018, 36, 103-113.	1.2	19
79	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). Journal of Clinical Oncology, 2018, 36, 1232-1239.	0.8	207
80	Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors. , 2018, 6, 93.		59
81	A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L).. Journal of Clinical Oncology, 2018, 36, 11514-11514.	0.8	30
82	Phase Ib/2a study of PLX51107, a small molecule BET inhibitor, in subjects with advanced hematological malignancies and solid tumors.. Journal of Clinical Oncology, 2018, 36, 2550-2550.	0.8	25
83	Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.. Journal of Clinical Oncology, 2018, 36, 3012-3012.	0.8	58
84	Redirected T cell lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: Overall survival findings.. Journal of Clinical Oncology, 2018, 36, 9521-9521.	0.8	41
85	Characterization and spatial localization of the tumor immune microenvironment in metastatic uveal melanoma.. Journal of Clinical Oncology, 2018, 36, 9570-9570.	0.8	3
86	Quantitative multiplex immunofluorescence to identify candidate biomarkers of response to anti-PD1 in metastatic melanoma.. Journal of Clinical Oncology, 2018, 36, e21600-e21600.	0.8	1
87	Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology, 2018, 36, 603-603.	0.8	17
88	Clonal evolution of uveal melanoma metastases.. Journal of Clinical Oncology, 2018, 36, e21534-e21534.	0.8	0
89	Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. Journal of Cancer Research and Clinical Oncology, 2017, 143, 439-445.	1.2	10
90	Metastatic disease from uveal melanoma: treatment options and future prospects. British Journal of Ophthalmology, 2017, 101, 38-44.	2.1	287

#	ARTICLE	IF	CITATIONS
91	Adopting a new stance on immunotherapy for uveal melanoma. <i>Lancet Oncology</i> , The, 2017, 18, 702-704.	5.1	4
92	Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017, 25, 2155-2167.	1.0	14
93	Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. <i>Melanoma Research</i> , 2017, 27, 57-64.	0.6	39
94	Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. <i>Current Oncology Reports</i> , 2017, 19, 45.	1.8	70
95	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4119-4126.	3.2	17
96	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. <i>Clinical Cancer Research</i> , 2017, 23, 2972-2980.	3.2	106
97	Mucosal melanoma: epidemiology, biology, management and the role of immunotherapy. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 945-952.	0.5	0
98	Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1249-1264.	2.0	56
99	Uveal melanoma: epidemiology, etiology, and treatment of primary disease. <i>Clinical Ophthalmology</i> , 2017, Volume 11, 279-289.	0.9	240
100	A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2523-2523.	0.8	6
101	Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9531-9531.	0.8	18
102	Outcomes of melanoma brain metastases treated with stereotactic radiosurgery with and without concurrent immune checkpoint therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21026-e21026.	0.8	0
103	Multi-center phase Ib study of intermittent dosing of the MEK inhibitor, selumetinib, in patients with advanced uveal melanoma not previously treated with a MEK inhibitor.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9597-TPS9597.	0.8	0
104	Reply to A. Indini et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 1018-1019.	0.8	0
105	Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment. <i>Experimental Dermatology</i> , 2016, 25, 553-554.	1.4	17
106	A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. <i>Melanoma Research</i> , 2016, 26, 272-277.	0.6	31
107	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. <i>Head and Neck</i> , 2016, 38, 1310-1317.	0.9	65
108	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. <i>Gynecologic Oncology Reports</i> , 2016, 16, 42-46.	0.3	40

#	ARTICLE	IF	CITATIONS
109	Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives. <i>Future Oncology</i> , 2016, 12, 1331-1344.	1.1	24
110	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	2.0	288
111	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016, 21, 848-854.	1.9	154
112	Melanoma driver mutations and immune therapy. <i>Oncolmmunology</i> , 2016, 5, e1051299.	2.1	13
113	The promise and challenges of rare cancer research. <i>Lancet Oncology</i> , The, 2016, 17, 136-138.	5.1	38
114	Evaluating Chemotherapy at the End of Life. <i>JAMA Oncology</i> , 2016, 2, 142.	3.4	0
115	Selumetinib for the treatment of melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 223-231.	0.5	1
116	Treatment of Uveal Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 281-293.	0.2	18
117	Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 1011-1011.	0.8	13
118	A first in human phase I study of receptor tyrosine kinase (RTK) inhibitor MGCD516 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2575-2575.	0.8	16
119	A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2581-2581.	0.8	20
120	A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT).. <i>Journal of Clinical Oncology</i> , 2016, 34, 3024-3024.	0.8	15
121	Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4568-4568.	0.8	26
122	Efficacy and safety of programmed death receptor-1 (PD-1) blockade in metastatic uveal melanoma (UM).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9507-9507.	0.8	5
123	A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9511-9511.	0.8	42
124	Frequency of actionable somatic alterations with genomic profiling: the Columbia University experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23132-e23132.	0.8	0
125	Update on the treatment of uveal melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2016, 14, 768-770.	0.3	2
126	Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.		95

#	ARTICLE	IF	CITATIONS
127	A First-in-Human Phase I Study of MORAb-004, a Monoclonal Antibody to Endosialin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1281-1288.	3.2	50
128	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition. <i>Clinical Cancer Research</i> , 2015, 21, 2289-2296.	3.2	128
129	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. <i>Cancer Immunology Research</i> , 2015, 3, 288-295.	1.6	145
130	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. <i>Human Pathology</i> , 2015, 46, 357-365.	1.1	252
131	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. <i>Oncologist</i> , 2015, 20, 789-797.	1.9	57
132	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. <i>Oncologist</i> , 2015, 20, 648-652.	1.9	38
133	A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas. <i>Oncologist</i> , 2015, 20, 1245-1246.	1.9	25
134	Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). <i>BMC Cancer</i> , 2015, 15, 467.	1.1	45
135	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015, 33, 3193-3198.	0.8	892
136	Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials. <i>Oncotarget</i> , 2015, 6, 19316-19327.	0.8	13
137	A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS9089-TPS9089.	0.8	0
138	Programmed death 1 immune checkpoint inhibitors. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 858-68.	0.3	19
139	Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. <i>Science Translational Medicine</i> , 2014, 6, 260ra149.	5.8	589
140	GNAQ and GNA11 mutations in uveal melanoma. <i>Melanoma Research</i> , 2014, 24, 525-534.	0.6	99
141	Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2397.	3.8	359
142	Ipilimumab in patients with melanoma and autoimmune disease. , 2014, 2, 35.		82
143	Treatments for Noncutaneous Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 507-521.	0.9	12
144	Selecting Patients for KIT Inhibition in Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 137-162.	0.4	4

#	ARTICLE	IF	CITATIONS
145	Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2014, 32, 9030-9030.	0.8	38
146	Landscape of genetic alterations in patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2014, 32, 9043-9043.	0.8	11
147	Assessment of overall survival from time of metastastasis in mucosal, uveal, and cutaneous melanoma.. Journal of Clinical Oncology, 2014, 32, 9074-9074.	0.8	13
148	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. Clinical Cancer Research, 2013, 19, 2257-2264.	3.2	136
149	Clinical activity of ipilimumab for metastatic uveal melanoma. Cancer, 2013, 119, 3687-3695.	2.0	171
150	Ipilimumab for Patients With Advanced Mucosal Melanoma. Oncologist, 2013, 18, 726-732.	1.9	140
151	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. , 2013, 1, 20.		31
152	Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).. Journal of Clinical Oncology, 2013, 31, CRA9003-CRA9003.	0.8	25
153	Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 345-356.	2.3	117
154	Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance. Clinical Cancer Research, 2012, 18, 3552-3561.	3.2	91
155	KIT as a Therapeutic Target in Metastatic Melanoma. JAMA - Journal of the American Medical Association, 2011, 305, 2327.	3.8	755
156	Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma. Clinical Cancer Research, 2011, 17, 2087-2100.	3.2	103
157	A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer. Pancreatology, 2009, 9, 404-409.	0.5	37
158	Aurora Kinases: New Targets for Cancer Therapy. Clinical Cancer Research, 2006, 12, 6869-6875.	3.2	258
159	Ewing's Sarcoma and Primitive Neuroectodermal Family of Tumors. Hematology/Oncology Clinics of North America, 2005, 19, 501-525.	0.9	124